JMP Securities Reiterates Market Outperform on Iovance Biotherapeutics, Maintains $18 Price Target
Benzinga · 6d ago
JMP Securities analyst Reni Benjamin reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and maintains $18 price target.